Core Insights - Akeso, Inc. has received approval from the National Medical Products Administration in China to initiate Phase II clinical trials for its bispecific antibody AK139, targeting multiple respiratory and autoimmune indications [1] - The indications for AK139 include chronic obstructive pulmonary disease (COPD), severe bronchial asthma, chronic spontaneous urticaria, allergic rhinitis, chronic rhinosinusitis with nasal polyps, moderate-to-severe atopic dermatitis, and prurigo nodularis [1] - AK139 is the first bispecific antibody targeting IL-4R and ST2 pathways, aiming to address significant unmet clinical needs in chronic inflammatory diseases [1] Company Overview - Akeso is a leading biopharmaceutical company founded in 2012, focusing on the research, development, manufacturing, and commercialization of innovative biological medicines [2] - The company has developed a robust R&D ecosystem centered on its proprietary Tetrabody bispecific antibody platform and has over 50 innovative assets in its pipeline, with 26 candidates currently in clinical trials [2] - Akeso aims to provide affordable therapeutic antibodies and create significant commercial and social value, positioning itself as a global leader in the biopharmaceutical industry [2]

Core Viewpoint - Akeso, Inc. has received its fifth Breakthrough Therapy Designation for ivonescimab, a bispecific antibody targeting PD-1 and VEGF, for the first-line treatment of advanced biliary tract cancer, highlighting its clinical potential across multiple tumor types [1][2]. Company Overview - Akeso is a leading biopharmaceutical company focused on the research, development, manufacturing, and commercialization of innovative biological medicines, with a robust R&D ecosystem centered on its proprietary Tetrabody bispecific antibody platform and other advanced technologies [9][10]. - The company has a pipeline of over 50 innovative assets, with 26 candidates currently in clinical trials, including 15 bispecific/multispecific antibodies and bispecific ADCs [10]. Clinical Development - The Phase III clinical study (AK112-309/HARMONi-GI1) is evaluating ivonescimab in combination with chemotherapy against durvalumab plus chemotherapy for advanced biliary tract cancer, with patient enrollment completed [3]. - Encouraging results from a Phase 1b/II study showed ivonescimab plus chemotherapy achieved an Objective Response Rate (ORR) of 63.6% and a Disease Control Rate (DCR) of 100%, with a median Progression-Free Survival (mPFS) of 8.5 months and a median Overall Survival (mOS) of 16.8 months [4][5].

Summary of Key Points from the Conference Call Industry Overview - **Industry**: China Biotechnology - **Market Outlook**: The overall view of the China Healthcare industry is considered attractive, indicating potential growth opportunities in the sector [3][6]. Company-Specific Catalysts Abbisko Cayman Ltd (2256.HK) - **Catalyst**: ABSK043 (oral PD-L1) Phase 2 data on 6-month PFS in treated EGFRm+ NSCLC expected in 1Q26 - **Importance**: High - **Surprise Potential**: Modest upside surprise anticipated - **Key Takeaways**: - Safety data from ESMO Asia 2025 is expected to guide therapeutic potential and outlook for dose expansion in 1L EGFRm+ NSCLC patients [6][7]. Akeso, Inc. (9926.HK) - **Catalyst**: Gumokimab (AK111) NMPA BLA approval for moderate-to-severe plaque psoriasis in 1Q26 - **Importance**: Neutral - **Surprise Potential**: In-line - **Key Takeaways**: - Revenue forecast of approximately Rmb1,037 million by 2030, with a 90% probability of success (PoS) [6][7]. Duality Biotherapeutics Inc (9606.HK) - **Catalyst**: DB-1311 (B7H3 ADC) data update for 2L+ mCRPC in 1Q26 - **Importance**: High - **Surprise Potential**: In-line - **Key Takeaways**: - Previous data showed median rPFS of 8.3 months, competitive against other therapies [7][8]. Everest Medicines Ltd (1952.HK) - **Catalyst**: Etrasimod NMPA NDA approval for moderate-to-severe UC in 1Q26 - **Importance**: High - **Surprise Potential**: In-line - **Key Takeaways**: - Revenue forecast of approximately Rmb1,192 million by 2030, with an 88% PoS [7][8]. HUTCHMED (China) Ltd (0013.HK) - **Catalyst**: Sovleplenib (HMPL-523) NMPA BLA re-submission in ITP/wAIHA in 1Q26 - **Importance**: Neutral - **Surprise Potential**: In-line - **Key Takeaways**: - Revenue forecast revised down to US$126 million by 2030, with a 79% PoS [7][8]. InnoCare Pharma Ltd (9969.HK) - **Catalyst**: Orelabrutinib (BTK) Phase 3 ITP data readout in 1Q26 - **Importance**: Neutral - **Surprise Potential**: In-line - **Key Takeaways**: - Cross-read from Roche's fenebrutinib Phase 3 data expected to provide insights [10][12]. Keymed Biosciences Inc. (2162.HK) - **Catalyst**: Enrollment completion in Phase 1 study for obesity expected by YE25 - **Importance**: Neutral - **Surprise Potential**: In-line - **Key Takeaways**: - Anticipated data availability in late 1Q26, with a competitive clinical profile expected [22][23]. Zai Lab Ltd (ZLAB.O) - **Catalyst**: Povetacicept (BAFF/APRIL) Phase 3 data presentation in 1Q26 - **Importance**: Neutral - **Surprise Potential**: Modest upside surprise - **Key Takeaways**: - Revenue forecast of Rmb2,196 million for 2030, indicating market discounts on asset potential [39][40]. Additional Insights - **Market Trends**: The therapeutic landscape is evolving, with a focus on oral therapies gaining traction against injectable options [6][7]. - **Regulatory Environment**: Companies are navigating complex regulatory landscapes, impacting timelines and revenue forecasts [7][8]. - **Investment Considerations**: Investors are advised to consider the potential for modest upside surprises in upcoming data releases, particularly in the context of current valuations and market expectations [39][40].

Core Insights - Akeso, Inc. has successfully included all five of its self-developed innovative drugs in the updated National Reimbursement Drug List (NRDL) for 2025, effective January 1, 2026, which enhances patient access to these treatments [1][2][3] Group 1: Drug Inclusion Details - All approved indications for Akeso's five independently commercialized drugs are now part of the NRDL, addressing major tumor diseases and autoimmune disorders prevalent in China [1][2] - Ivonescimab, a first-in-class PD-1/VEGF bispecific antibody, has secured inclusion for its new first-line indication for PD-L1-positive non-small cell lung cancer (NSCLC), demonstrating a 49% reduction in disease progression or death compared to pembrolizumab in clinical trials [3][4] - Cadonilimab, another first-in-class bispecific antibody, has successfully negotiated inclusion for first-line indications in gastric and cervical cancers, showing significant clinical benefits across all patient populations [4] - Penpulimab has achieved NRDL inclusion for all four of its approved indications, including treatments for nasopharyngeal carcinoma and classical Hodgkin lymphoma [5] - Ebdarokimab, targeting IL-12/IL-23, has been included for the treatment of moderate-to-severe psoriasis, marking Akeso's first drug in the autoimmune disease sector [7] - Ebronucimab has secured inclusion for both of its approved indications related to hypercholesterolemia, enhancing its market presence [8] Group 2: Strategic Implications - The successful inclusion of these drugs in the NRDL is expected to reduce the financial burden on patients and provide superior treatment alternatives, thereby addressing significant public health challenges in China [2] - The recognition of these drugs in clinical practice prior to NRDL inclusion indicates their breakthrough clinical value and enhances trust among healthcare providers and patients [2] - This achievement lays a solid foundation for accelerating broader clinical adoption and supports Akeso's ongoing commercialization efforts, positioning the company for sustained growth and global expansion [2][3] Group 3: Company Overview - Akeso is a leading biopharmaceutical company focused on the research, development, manufacturing, and commercialization of innovative biological medicines, with a robust pipeline of over 50 assets in various therapeutic areas [12] - The company utilizes an integrated R&D innovation system and has developed a comprehensive drug development platform, which includes bispecific antibody technology [12] - Akeso aims to provide affordable therapeutic antibodies globally while creating significant commercial and social value, striving to become a leading player in the biopharmaceutical industry [12]

Core Insights - Akeso, Inc. has received approval from the National Medical Products Administration (NMPA) to initiate clinical trials for its bispecific antibody AK152, targeting Alzheimer's Disease [1][2]. Company Overview - Akeso is a leading biopharmaceutical company founded in 2012, focusing on innovative biological medicines and has developed a comprehensive end-to-end drug development platform [10]. - The company has a robust pipeline of over 50 innovative assets across various disease areas, with 24 candidates currently in clinical trials [10]. Product Development - AK152 is the first bispecific antibody developed in China aimed at disease-modifying therapy for Alzheimer's Disease, marking a significant breakthrough in the field [2]. - The antibody targets both amyloid-beta (A) and a receptor expressed on the blood-brain barrier (BBB), enhancing brain penetration and therapeutic efficacy [4][6]. Mechanism of Action - AK152 binds to amyloid-beta plaques and selectively targets neurotoxic soluble A oligomers, while also utilizing receptor-mediated endocytosis to improve brain penetration [4][6]. - Preclinical studies indicate that AK152 significantly improves brain penetration and accelerates the clearance of A plaques compared to conventional monoclonal antibodies [5][6]. Clinical Significance - The development of AK152 addresses critical unmet clinical needs in treating Alzheimer's Disease, which has long posed therapeutic challenges globally [5]. - The promising preclinical results suggest that AK152 could become a next-generation disease-modifying therapy for Alzheimer's patients [6].

Core Insights - Akeso, Inc. has initiated a Phase I clinical trial for its personalized mRNA vaccine AK154, targeting pancreatic cancer as both a monotherapy and in combination with bispecific antibodies cadonilimab and ivonescimab [1][2][4] Company Overview - Akeso is a leading biopharmaceutical company founded in 2012, focusing on innovative biological medicines and has developed a comprehensive end-to-end drug development platform [8] - The company has over 50 innovative assets in its pipeline, with 24 candidates currently in clinical trials, including 15 bispecific/multispecific antibodies [8] Product Development - AK154 is Akeso's first mRNA-based therapeutic candidate, designed to address the "cold tumor" phenotype in pancreatic cancer by utilizing sequence-specific mRNA vaccines [2][3] - Preclinical data for AK154 indicates strong immunogenicity and anti-tumor activity, suggesting a favorable safety profile when combined with Akeso's bispecific antibodies [4]

Core Insights - Akeso, Inc. has presented preclinical research data for its novel monoclonal antibody AK135, targeting IL-1RAP, at the 40th Annual Meeting of the Society for Immunotherapy of Cancer [1][2] Group 1: Product Development - AK135 effectively targets IL-1RAP and blocks three key pro-inflammatory signaling pathways—IL-1, IL-33, and IL-36, providing significant pain relief in neuropathy with good tolerability and safety profiles [2][6] - The antibody is currently in Phase I clinical trials for treating chemotherapy-induced peripheral neuropathy (CIPN) [6][11] - Preclinical studies indicate that AK135 shows dose-dependent efficacy in alleviating neuropathic pain and maintains stable body weight in treated models without significant toxicity [8] Group 2: Market Context - CIPN affects 50-90% of chemotherapy-treated patients, with 30-40% progressing to chronic neuropathic pain, highlighting the clinical significance of effective treatment options [5] - Akeso's development of AK135 addresses a critical gap in treatment options for CIPN, as current effective therapies are limited [5][6] Group 3: Company Overview - Akeso is a leading biopharmaceutical company focused on innovative biological medicines, with a robust pipeline of over 50 innovative assets across various disease areas, including cancer and autoimmune diseases [11] - The company has developed a comprehensive end-to-end drug development platform and has 24 candidates in clinical trials, including 15 bispecific/multispecific antibodies [11]

Summary of Key Points from the Conference Call Industry or Company Involved - The discussion primarily revolves around the **China Equity Strategy** and the implications of recent **US-China trade talks** on various sectors and companies within the Chinese market. Core Insights and Arguments 1. **Trade Talk Outcomes**: Recent trade talks yielded better-than-expected results, particularly concerning the reduction of fentanyl-related tariffs from 20% to 10% and the rollback of the 100% tariff hike against China announced in early October 2025 [5][2][3]. 2. **Market Recovery Potential**: Despite some major indices not fully recovering, particularly HSTECH which remains 6% below its October 9 level, there is potential for market catch-up and optimism if state visits by leaders occur in the coming quarters [2][3]. 3. **Sector Benefits**: Sectors likely to benefit from improved US-China relations include **hardware tech**, **healthcare**, and **internet**. Specific stocks with significant potential for recovery have been identified based on their performance since the tariff announcements [2][4]. 4. **Profit-Taking Concerns**: There has been some profit-taking in new consumption and biotech names, averaging a decline of approximately 8% over the last four weeks. However, historical data suggests that MSCI China typically delivers an average return of 8% in the fourth quarter following positive returns in the preceding three quarters [3][14]. 5. **TMT Sector Performance**: The Technology, Media, and Telecommunications (TMT) sector is expected to continue strong performance due to attractive valuations, strong earnings momentum (hardware tech earnings up approximately 50% in Q2 2025), and robust guidance on AI-related spending from US hyperscalers [3][14]. 6. **Rebound Positioning**: Sectors that rebounded the most after the April trough and have underperformed since the tariff news are likely to see significant recovery potential. These include **data centers**, **sportswear**, **online gaming**, **consumer finance**, **pharma retail**, and **tech hardware** [4][3]. 7. **Earnings Risks**: Sectors with the highest potential earnings risks from tariffs include **machinery**, **pet products**, **sportswear OEM**, **biotech**, and **tech hardware** [4]. Other Important but Possibly Overlooked Content 1. **Historical Performance Data**: The report highlights that since 2000, MSCI China has had positive returns in over 60% of instances when the first three quarters recorded positive returns [14]. 2. **Government Policy Support**: Continued government support for technological innovation is indicated in the 15th five-year plan, which may further bolster the TMT sector [3]. 3. **Individual Stock Performance**: A list of buy-rated stocks that have declined significantly since October 9, 2025, includes companies across various sectors, indicating potential investment opportunities [13][37]. 4. **Market Risks**: Risks facing China's equities include a potential hard landing in the property market, capital exodus due to currency depreciation, and slow structural reform progress. Inadequate government policies could lead to market shocks [25]. This summary encapsulates the key points discussed in the conference call, providing insights into the current state and future outlook of the Chinese equity market in light of recent trade developments.

Group 1 - The article does not provide any specific content related to a company or industry, as it appears to be a technical issue regarding browser settings and ad-blockers [1]

Core Insights - Ivonescimab combined with chemotherapy demonstrated a 40% reduction in the risk of disease progression or death compared to Tislelizumab plus chemotherapy in the first-line treatment of patients with squamous non-small cell lung cancer (NSCLC) in the HARMONi-6 study [1][5][33] - The median progression-free survival (PFS) was 11.14 months for Ivonescimab plus chemotherapy versus 6.90 months for Tislelizumab plus chemotherapy, with a hazard ratio of 0.60 [1][5][6] - The safety profile of Ivonescimab was comparable to Tislelizumab, with similar rates of serious treatment-related adverse events (TRAEs) and discontinuation due to TRAEs [1][7][9] Study Overview - The HARMONi-6 trial was a Phase III, multi-center study conducted in China, evaluating Ivonescimab in combination with platinum-based chemotherapy against Tislelizumab plus chemotherapy in patients with advanced squamous NSCLC, regardless of PD-L1 expression [2][4][33] - The study was sponsored by Akeso, Inc., with all relevant data generated and analyzed by Akeso [2][4] Efficacy Results - Ivonescimab showed a statistically significant improvement in PFS, with a hazard ratio of 0.60 (95% CI: 0.46, 0.78; p<0.0001) [5][6] - The overall response rate (ORR) was 75.9% for Ivonescimab plus chemotherapy compared to 66.5% for Tislelizumab plus chemotherapy [6] - Duration of response (DoR) was also longer for Ivonescimab at 11.20 months versus 8.38 months for Tislelizumab [6] Safety Profile - The safety profile of Ivonescimab was manageable, with 3.4% of patients discontinuing due to TRAEs compared to 4.2% for Tislelizumab [9][11] - Serious TRAEs occurred in 32.3% of patients receiving Ivonescimab and 30.2% for Tislelizumab [11] - Grade 3 or higher immune-related adverse events were reported in 9.0% of Ivonescimab patients versus 10.2% for Tislelizumab [11] Future Studies - The HARMONi-3 global study will analyze squamous and non-squamous NSCLC cohorts separately, with enrollment completion expected in the first half of 2026 for the squamous cohort and the second half of 2026 for the non-squamous cohort [1][19][20] - An interim analysis for overall survival is planned for both cohorts upon reaching the prespecified number of events [19][20] Publication and Presentation - The results of the HARMONi-6 trial were published in The Lancet and presented at the European Society for Medical Oncology (ESMO) 2025 Congress [1][13][24]